Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GI DYNAMICS, INC.GID · Entity 141502 | Director | February 28, 2020 | March 05, 2020 |
| KIORA PHARMACEUTICALS INCKPRX · Entity 7940 | Director | June 10, 2026 | June 12, 2026 |
| LEXICON PHARMACEUTICALS, INC.LXRX · Entity 4970 | EVP, R&D | February 28, 2021 | March 02, 2021 |
| Skye Bioscience, Inc.SKYE · Entity 8098 | Director | February 29, 2024 | March 04, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GI DYNAMICS, INC.
Report date February 28, 2020 · Filed March 05, 2020
This filing explicitly reported no securities owned.
KIORA PHARMACEUTICALS INC
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.63 · Expires 2036-06-10 | Direct | 40,000 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 40,000 · Balance 40,000 F1: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on June 10, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on June 10, 2027.
LEXICON PHARMACEUTICALS, INC.
Report date February 28, 2021 · Filed March 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 120,791 |
Ending reported balance
After 2021-02-28 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2021-02-28 · Exercise / conversion · Acquired 2,990 · Balance 72,334 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. Row 2 · 2021-02-28 · Exercise / conversion · Acquired 9,727 · Balance 82,061 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. Row 3 · 2021-02-28 · Exercise / conversion · Acquired 26,600 · Balance 108,661 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. Row 4 · 2021-02-28 · Exercise / conversion · Acquired 28,690 · Balance 137,351 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. Row 5 · 2021-02-28 · Tax withholding · Disposed 16,560 · Balance 120,791 F2: Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-02-28 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-02-28 · Exercise / conversion · Disposed 2,990 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. F3: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2018 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-02-28 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-02-28 · Exercise / conversion · Disposed 9,727 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. F4: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2019 and vest an additional one third on February 28 of each of the two succeeding years thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 26,600 |
Reported balance
After 2021-02-28 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-02-28 · Exercise / conversion · Disposed 26,600 · Balance 26,600 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. F5: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2020 and vest an additional one third on February 28 of each of the two succeeding years thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 57,380 |
Reported balance
After 2021-02-28 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-02-28 · Exercise / conversion · Disposed 28,690 · Balance 57,380 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. F6: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock.
F2: Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.
F3: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2018 and vest an additional 25% on February 28 of each of the three succeeding years thereafter.
F4: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2019 and vest an additional one third on February 28 of each of the two succeeding years thereafter.
F5: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2020 and vest an additional one third on February 28 of each of the two succeeding years thereafter.
F6: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.
Skye Bioscience, Inc.
Report date February 29, 2024 · Filed March 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.56 · Expires 2034-03-01 | Direct | 35,000 |
Reported balance
After 2024-02-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-29 · Grant · Acquired 35,000 · Balance 35,000 F1: The option grant shall be exercisable for a price of $14.56 per option share for ten years from February 29, 2024 and the options will vest in equal monthly installments over the one year period beginning February 29, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The option grant shall be exercisable for a price of $14.56 per option share for ten years from February 29, 2024 and the options will vest in equal monthly installments over the one year period beginning February 29, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 12, 2026 16:13 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0001372514-26-000061 · wk-form4_1781295224.xml · derivative · entry 1 TYLE PRAVEEN · CIK 0001296936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on June 10, 2027. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 20:14 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001372514-25-000027 · wk-form4_1743639259.xml · derivative · entry 1 TYLE PRAVEEN · CIK 0001296936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-04-01 F1 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on April 1, 2026. Read SEC document |
| August 19, 2024 Filed Aug 19, 2024 15:45 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | PurchaseCommon Stock | 5,000 | $3.96 | $19,800.00 |
DisclosureSEC source: 0001372514-24-000109 · wk-form4_1724096730.xml · nonDerivative · entry 1 TYLE PRAVEEN · CIK 0001296936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,014 Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 15:15 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 1,778 | $0.00 Strike: $4.35 | $0.00 |
DisclosureSEC source: 0001372514-24-000088 · wk-form4_1720034108.xml · derivative · entry 1 TYLE PRAVEEN · CIK 0001296936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,778 Underlying: Common Stock · 1,778 shares Expires 2034-07-01 F1 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on July 1, 2025. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 06:20 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $14.56 | $0.00 |
DisclosureSEC source: 0001516551-24-000022 · wk-form4_1709551223.xml · derivative · entry 1 TYLE PRAVEEN · CIK 0001296936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2034-03-01 F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $14.56 per option share for ten years from February 29, 2024 and the options will vest in equal monthly installments over the one year period beginning February 29, 2024. Read SEC document |
| November 06, 2023 Filed Nov 6, 2023 20:29 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 14,110 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001516551-23-000092 · wk-form4_1699320545.xml · derivative · entry 1 TYLE PRAVEEN · CIK 0001296936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,001 Underlying: Common Stock · 14,110 shares Expires 2033-08-25 F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $3.50 per option share for ten years from August 25, 2023 and the options will vest in equal monthly installments over the one year period beginning August 24, 2023. Read SEC document |
| September 29, 2023 Filed Oct 3, 2023 16:46 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001372514-23-000147 · wk-form4_1696365983.xml · derivative · entry 1 TYLE PRAVEEN · CIK 0001296936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2033-09-29 F1 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become fully exercisable on September 29, 2024. Read SEC document |
| August 25, 2023 Filed Aug 29, 2023 18:22 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 1,472,692 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0001516551-23-000060 · wk-form4_1693347739.xml · derivative · entry 1 TYLE PRAVEEN · CIK 0001296936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,472,692 Underlying: Common Stock · 1,472,692 shares Expires 2033-08-25 F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $0.014 per option share for ten years from August 25, 2023 and the options will vest in equal monthly installments over the one year period beginning August 24, 2023. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 20:14 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $3.83 | $0.00 |
DisclosureSEC source: 0001372514-23-000031 · wf-form4_167823803026213.xml · derivative · entry 1 TYLE PRAVEEN · CIK 0001296936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2033-03-03 F1 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become fully exercisable on March 3, 2024. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 17:21 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $0.02 | $0.00 |
DisclosureSEC source: 0001516551-23-000006 · wf-form4_167304366212912.xml · derivative · entry 1 TYLE PRAVEEN · CIK 0001296936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2033-01-05 F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $0.017 per option share for ten years from January 5, 2023 (the "Grant Date") and the options will vest in equal monthly installments over the one year period from the Grant Date. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 11:28 UTC Amendment | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $0.02 | $0.00 |
DisclosureSEC source: 0001516551-23-000014 · wf-form4a_167328166436192.xml · derivative · entry 1 TYLE PRAVEEN · CIK 0001296936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2033-01-05 F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $0.017 per option share for ten years from January 5, 2023 (the "Grant Date") and the options will vest in equal monthly installments over the one year period from December 8, 2022. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 19:06 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001104659-22-011497 · tm225348d9_4.xml · derivative · entry 1 TYLE PRAVEEN · CIK 0001296936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become fully exercisable on February 1, 2023. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 16:01 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantDirector Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.12 | $0.00 |
DisclosureSEC source: 0001628280-21-018754 · wf-form4_163182245212535.xml · derivative · entry 1 TYLE PRAVEEN · CIK 0001296936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 25,000 shares Expires 2031-09-14 F1 · derivative.exercise_date: The Option shall be exercisable for a price of $0.12 per Option Share in twelve equal monthly installments such that all the Option Shares shall vest in twelve months. Read SEC document |
| July 22, 2021 Filed Jul 26, 2021 14:23 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantDirector Option Grant (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $0.14 | $0.00 |
DisclosureSEC source: 0001140361-21-025590 · form4.xml · derivative · entry 1 TYLE PRAVEEN · CIK 0001296936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2031-07-22 F1 · derivative.exercise_date: Each of the Options shall be exercisable for a price of $0.14 per Option Share for ten years from July 22, 2021 (the "Grant Date") and all Options will vest 10% on the Grant Date and 90% in equal semiannual installments over two years. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 22:00 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 28,690 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-008777 · form4.xml · derivative · entry 9 TYLE PRAVEEN · CIK 0001296936 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,380 Underlying: Common Stock · 28,690 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F6 · derivative.exercise_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. F6 · derivative.expiration_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 22:00 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 26,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-008777 · form4.xml · derivative · entry 8 TYLE PRAVEEN · CIK 0001296936 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,600 Underlying: Common Stock · 26,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2020 and vest an additional one third on February 28 of each of the two succeeding years thereafter. F5 · derivative.expiration_date: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2020 and vest an additional one third on February 28 of each of the two succeeding years thereafter. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 22:00 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 9,727 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-008777 · form4.xml · derivative · entry 7 TYLE PRAVEEN · CIK 0001296936 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,727 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2019 and vest an additional one third on February 28 of each of the two succeeding years thereafter. F4 · derivative.expiration_date: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2019 and vest an additional one third on February 28 of each of the two succeeding years thereafter. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 22:00 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 2,990 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-008777 · form4.xml · derivative · entry 6 TYLE PRAVEEN · CIK 0001296936 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,990 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2018 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. F3 · derivative.expiration_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2018 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 22:00 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Tax withholdingCommon Stock | 16,560 | $7.19 | $119,066.40 |
DisclosureSEC source: 0001127602-21-008777 · form4.xml · nonDerivative · entry 5 TYLE PRAVEEN · CIK 0001296936 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,791 F2 · kind: Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 22:00 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 28,690 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-008777 · form4.xml · nonDerivative · entry 4 TYLE PRAVEEN · CIK 0001296936 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 22:00 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 26,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-008777 · form4.xml · nonDerivative · entry 3 TYLE PRAVEEN · CIK 0001296936 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,661 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 22:00 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 9,727 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-008777 · form4.xml · nonDerivative · entry 2 TYLE PRAVEEN · CIK 0001296936 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 22:00 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 2,990 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-008777 · form4.xml · nonDerivative · entry 1 TYLE PRAVEEN · CIK 0001296936 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,334 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 21:41 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 96,310 | $0.00 Strike: $8.38 | $0.00 |
DisclosureSEC source: 0001127602-21-005882 · form4.xml · derivative · entry 2 TYLE PRAVEEN · CIK 0001296936 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,310 Underlying: Common Stock · 96,310 shares Expires 2031-02-11 F3 · derivative.exercise_date: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 21:41 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantRestricted Stock Units · Derivative | 32,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-005882 · form4.xml · derivative · entry 1 TYLE PRAVEEN · CIK 0001296936 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,100 Underlying: Common Stock · 32,100 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. F2 · derivative.expiration_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 21:53 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | GrantStock Option (right to buy) · Derivative | 3,333 | $0.00 Strike: $6.46 | $0.00 |
DisclosureSEC source: 0001104659-21-011849 · tm215262-7_4seq1.xml · derivative · entry 1 TYLE PRAVEEN · CIK 0001296936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 Underlying: Common Stock · 3,333 shares Expires 2031-02-01 F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become fully exercisable on February 1, 2022. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 21:20 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Tax withholdingCommon Stock | 4,844 | $1.96 | $9,494.24 |
DisclosureSEC source: 0001127602-20-014494 · form4.xml · nonDerivative · entry 2 TYLE PRAVEEN · CIK 0001296936 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,344 F2 · kind: Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 21:20 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantCommon Stock | 19,893 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-014494 · form4.xml · nonDerivative · entry 1 TYLE PRAVEEN · CIK 0001296936 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,188 F1 · kind: Issued upon vesting of performance-based restricted stock units granted on December 5, 2019, the vesting of which was determined by the compensation committee in its sole discretion based on pre-specified corporate goals. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:17 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 26,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-008968 · form4.xml · derivative · entry 6 TYLE PRAVEEN · CIK 0001296936 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,200 Underlying: Common Stock · 26,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2020 and vest an additional one third on February 28 of each of the two succeeding years thereafter. F4 · derivative.expiration_date: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2020 and vest an additional one third on February 28 of each of the two succeeding years thereafter. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:17 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 9,726 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-008968 · form4.xml · derivative · entry 5 TYLE PRAVEEN · CIK 0001296936 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,727 Underlying: Common Stock · 9,726 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2019 and vest an additional one third on February 28 of each of the two succeeding years thereafter. F3 · derivative.expiration_date: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2019 and vest an additional one third on February 28 of each of the two succeeding years thereafter. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:17 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 2,990 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-008968 · form4.xml · derivative · entry 4 TYLE PRAVEEN · CIK 0001296936 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,990 Underlying: Common Stock · 2,990 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2018 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. F2 · derivative.expiration_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2018 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:17 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 26,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-008968 · form4.xml · nonDerivative · entry 3 TYLE PRAVEEN · CIK 0001296936 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,295 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:17 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 9,726 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-008968 · form4.xml · nonDerivative · entry 2 TYLE PRAVEEN · CIK 0001296936 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,695 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:17 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 2,990 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-008968 · form4.xml · nonDerivative · entry 1 TYLE PRAVEEN · CIK 0001296936 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,969 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 16:32 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | GrantStock Option (right to buy) · Derivative | 3,333 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001104659-20-022846 · tm209305-6_4.xml · derivative · entry 1 TYLE PRAVEEN · CIK 0001296936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 Underlying: Common Stock · 3,333 shares Expires 2030-02-14 F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Plan. The Option will become fully exercisable on February 1, 2021. Read SEC document |
| February 06, 2020 Filed Feb 10, 2020 21:14 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 258,210 | $0.00 Strike: $3.31 | $0.00 |
DisclosureSEC source: 0001127602-20-004602 · form4.xml · derivative · entry 2 TYLE PRAVEEN · CIK 0001296936 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,210 Underlying: Common Stock · 258,210 shares Expires 2030-02-06 F3 · derivative.exercise_date: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter. Read SEC document |
| February 06, 2020 Filed Feb 10, 2020 21:14 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantRestricted Stock Units · Derivative | 86,070 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004602 · form4.xml · derivative · entry 1 TYLE PRAVEEN · CIK 0001296936 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,070 Underlying: Common Stock · 86,070 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. F2 · derivative.expiration_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 22:19 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 9,727 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-009267 · form4.xml · derivative · entry 4 TYLE PRAVEEN · CIK 0001296936 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,453 Underlying: Common Stock · 9,727 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2019 and vest an additional one third on February 28 of each of the two succeeding years thereafter. F3 · derivative.expiration_date: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2019 and vest an additional one third on February 28 of each of the two succeeding years thereafter. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 22:19 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 2,990 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-009267 · form4.xml · derivative · entry 3 TYLE PRAVEEN · CIK 0001296936 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,980 Underlying: Common Stock · 2,990 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2018 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. F2 · derivative.expiration_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2018 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 22:19 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 9,727 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-009267 · form4.xml · nonDerivative · entry 2 TYLE PRAVEEN · CIK 0001296936 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,979 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 22:19 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 2,990 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-009267 · form4.xml · nonDerivative · entry 1 TYLE PRAVEEN · CIK 0001296936 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,252 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 07, 2019 Filed Feb 8, 2019 23:13 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantRestricted Stock Units · Derivative | 79,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-004890 · form4.xml · derivative · entry 2 TYLE PRAVEEN · CIK 0001296936 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,800 Underlying: Common Stock · 79,800 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2020 and vest an additional one third on February 28 of each of the two succeeding years thereafter. F3 · derivative.expiration_date: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2020 and vest an additional one third on February 28 of each of the two succeeding years thereafter. Read SEC document |
| February 07, 2019 Filed Feb 8, 2019 23:13 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 148,200 | $0.00 Strike: $5.16 | $0.00 |
DisclosureSEC source: 0001127602-19-004890 · form4.xml · derivative · entry 1 TYLE PRAVEEN · CIK 0001296936 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,200 Underlying: Common Stock · 148,200 shares Expires 2029-02-07 F1 · derivative.exercise_date: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant (2/7/2020) and vests 1/48th per month for each month of service thereafter Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 16:37 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001144204-19-005044 · tv512444_form4.xml · derivative · entry 1 TYLE PRAVEEN · CIK 0001296936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-02-01 F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to 100% of the shares underlying the Option on February 1, 2020. Read SEC document |
| July 10, 2018 Filed Jul 12, 2018 16:52 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-038183 · tv498475_4.xml · nonDerivative · entry 1 TYLE PRAVEEN · CIK 0001296936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,893 F1 · shares: Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The restrictions will vest as to all of the shares on July 10, 2019. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:11 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 2,990 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-009734 · form4.xml · derivative · entry 3 TYLE PRAVEEN · CIK 0001296936 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,970 Underlying: Common Stock · 2,990 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2018 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. F3 · derivative.expiration_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2018 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:11 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Tax withholdingCommon Stock | 728 | $8.53 | $6,209.84 |
DisclosureSEC source: 0001127602-18-009734 · form4.xml · nonDerivative · entry 2 TYLE PRAVEEN · CIK 0001296936 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,262 F2 · kind: Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:11 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 2,990 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-009734 · form4.xml · nonDerivative · entry 1 TYLE PRAVEEN · CIK 0001296936 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,990 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 22:17 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 82,820 | $0.00 Strike: $9.79 | $0.00 |
DisclosureSEC source: 0001127602-18-005208 · form4.xml · derivative · entry 2 TYLE PRAVEEN · CIK 0001296936 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,820 Underlying: Common Stock · 82,820 shares Expires 2028-02-08 F3 · derivative.exercise_date: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant (2/8/2019) and vests 1/48th per month for each month of service thereafter. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 22:17 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantRestricted Stock Units · Derivative | 29,180 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-005208 · form4.xml · derivative · entry 1 TYLE PRAVEEN · CIK 0001296936 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,180 Underlying: Common Stock · 29,180 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2019 and vest an additional one third on February 28 of each of the two succeeding years thereafter. F2 · derivative.expiration_date: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2019 and vest an additional one third on February 28 of each of the two succeeding years thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.